Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome

American Journal of Cardiology

Volumn 93, Issue 11 SUPPL., 2004, Pages 3-11

  Davidson, Michael H ^a  

^a RADIANT RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; COLESEVELAM; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; B SCAN; CARDIOVASCULAR RISK; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DISEASE MARKER; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DYSLIPIDEMIA; ELECTRON BEAM TOMOGRAPHY; FOOD AND DRUG ADMINISTRATION; HIGH RISK POPULATION; HUMAN; HYPERTRIGLYCERIDEMIA; LIVER TOXICITY; LOW DRUG DOSE; METABOLIC SYNDROME X; MYOPATHY; PRIORITY JOURNAL; SCORING SYSTEM; ULTRASOUND;

EID: 2642560208     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.02.006     Document Type: Conference Paper

References (31)

1. Executive Summary of the third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389
3. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-235
4. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with CHD and a brand range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
6. American Diabetic Association. Clinical practice recommendations for patients with diabetes. Available at: http://www.diabetes.org/uedocuments/ Overview.pdf. Accessed January 12, 2004
7. Physician's Desk Reference. 2004. Montvale, NJ: Thompson Healthcare
8. Genest J., Frohlich J., Fodor G., McPherson R. Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ. 169:2003;921-924
9. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere D.R., Lagendorfer A., Stein E.A., Kruyer W., Gotto A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS/TexCAPS. JAMA. 279:1998;1615-1622
10. Walldius G., Jungner I., Holem I., Aastveit A.H., Kolar W., Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study) a prospective study. Lancet. 358:2001;2026-2033
11. Ballantyne C.M., Corsini A., Davidson M.H., Holdaas H., Jacobson T.A., Leitersdorf E., Marz W., Reckless J.P., Stein E.A. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 163:2003;1615-1616
12. Ridker P.M., Buring J.E., Cook N.R., Rifai N. C-reactive protein, the metabolic syndrome and risk of incident cardiovascular events. Circulation. 107:2003;391-397
13. Gardner C.D., Fortmann S.P., Krause R. Association of small LDL particles with incidence of coronary artery disease in men and women. JAMA. 276:1996;875-881
14. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, et al. American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. Circulation 2003;107:645-651
15. Sager PT, Melani L, Lipka L, Strony J, Yang B, Suresh R, Veltri E, for the Ezetimibe Study Group. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003;92:1414-1418
16. Nissen S. (REVERSAL) A prospective, randomized, double blind, multi-center study comparing the effects of atorvastatin vs. pravastatin on the progression of coronary atherosclerotic lesions as measured by intravascular ultrasound. American Heart Association Scientific Sessions; November 9-12, 2003; Orlando, Florida. Plenary Session XI: Late Breaking Clinical Trials
17. Ridker PM, for the JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003;108:2292-2297
18. Ridker P.M., Rifai N., Lynda R., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 347:2002;1557-1565
19. Campos H., Moye L.A., Glasser S.P., Stampger M.J., Sacks F.M. Low-density lipoprotein size, pravastatin treatment and coronary events. JAMA. 286:2001;1468-1474
20. Blake G.J., Otvos J.D., Rifai N., Ridker P.M. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 106:2002;1930-1937
21. Raggi P., Callister T.Q., Davidson M., Welty F.K., Bachmann G.A., Laskey R., Pittman D., Kafonek S., Scott R. Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. Am Heart J. 141:2001;722-726
22. Brewer H.B. Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol. 92:(suppl):2003;23K-29K
23. Davidson M.H. Combination therapy for dyslipidemia safety and regulatory considerations. Am J Cardiol. 90:(suppl):2002;50K-60K
24. Davidson M.H., Dicklin M.R., Maki K.C., Kleinpell R. Colesevelam hydrochloride a non-absorbed, polymeric cholesterol-lowering agent. Expert Opin Investig Drugs. 9:2000;2663-2671
25. Davidson M.H. Ezetimibe a novel option for lowering cholesterol. Expert Rev Cardiovasc Ther. 1:2003;11-21
26. Davidson M.H., McGarry T., Bettis R., Melani L., Lipka L.J., LeBeaut A.P., Suresh R., Sun S., Veltri E.P. Exetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 40:2002;2125-2134
27. Omar M.A., Wilson J.P., Cox T.S. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother. 35:2001;1096-1107
28. Prueksaritanont T., Zhao J.J., Ma B., Roadcap B.A., Tang C., Qiu Y., Liu L., Lin J.H., Pearson P.G., Baillie T.A. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther. 301:2002;1042-1051
29. Prueksaritanont T., Subramanian R., Fang X., Ma B., Qiu Y., Lin J.H., Pearson P.G., Baillie T.A. Glucuronidation of statins in animals and humans a novel mechanism of statin lactonization. Drug Metab Dispos. 30:2002;505-512
30. Davidson M.H. Controversy surrounding the safety of cerivastatin. Expert Opin Drug Saf. 1:2002;207-212
31. Robins SJ, Rubins HB, Faas FH, Schaeffer EJ, Elam MB, Adnerson JW, Collins D, for the VA-HIT Study Group. Insulin resistance and cardiovascular events with low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003;26:1513-1517